All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The prognosis for patients with fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) is poor, mainly due to early relapse and a lack of response to further treatment.1 Patients with FLT3-ITD AML in first complete remission often receive allogeneic stem cell transplantation (allo-SCT), however, relapse after allo-SCT has very low survival outcomes.2 The benefit of sorafenib as a monotherapy or in combination with other therapies in this setting remains unclear.
Professor Ali Bazarbachi, from the American University of Beirut, Beirut, LB, and colleagues published a report from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukaemia Working Party (ALWP), which assessed the safety and efficacy of sorafenib as a salvage therapy for adult patients with FLT3-ITD AML (n = 152) who relapsed or had disease progression following allo-SCT.3 This retrospective, registry-based, multicenter analysis examined the outcome of patients who received salvage therapy with sorafenib (n = 34; median age at allo-SCT = 48 years; range, 19–69) with patients who did not receive sorafenib salvage therapy (n = 118; median age = 51 years; range, 19–75). In addition, a pre-planned pair-matched analysis was also performed using data from 30 patients who had received sorafenib salvage compared to 30 patients who had not.
All findings shown as sorafenib group versus control group, where applicable
Based on this retrospective registry-based analysis the authors concluded that using sorafenib as a salvage therapy for patients with FLT3-ITD AML who relapsed or had disease progression following allo-SCT leads to improved survival. The administration of sorafenib as standard daily dose of 800 mg in two divided doses was safe, although dose modifications were frequently required.
Subscribe to get the best content related to AML delivered to your inbox